Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05000216 (ClinicalTrials.gov)	August 13, 2021	6/8/2021	COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders	Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01)	Rheumatoid Arthritis (RA);Systemic Lupus Erythematosus (SLE);Pemphigus Vulgaris;Multiple Sclerosis (MS);Systemic Sclerosis (SSc);Pediatric SLE;Juvenile Idiopathic Arthritis (JIA);Juvenile Dermatomyositis (JDM);Pediatric-Onset Multiple Sclerosis (POMS)	Biological: Moderna mRNA-1273;Biological: BNT162b2;Biological: Ad26.COV2.S;Drug: Continue IS (MMF or MPA);Drug: Continue IS (MTX);Biological: Continue IS (B cell depletion therapy);Biological: Monovalent [B.1.351] CoV2 preS dTM-AS03;Drug: Withhold IS (MMF or MPA);Drug: Withhold IS (MTX);Drug: Withhold IS (B cell depletion therapy);Biological: Moderna mRNA-1273 , Bivalent;Biological: BNT162b2 , Bivalent	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.	Recruiting	2 Years	N/A	All	2340	Phase 2	United States
2	NCT02644044 (ClinicalTrials.gov)	January 2016	23/3/2015	Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study	Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study	To Evaluate the Effect of Therapy With IT MTX on the Disease Course of Patients With Progressive MS	Drug: Intrathecal methotrexate	Tel-Aviv Sourasky Medical Center	NULL	Not yet recruiting	18 Years	75 Years	Both	30	Phase 0	NULL